Study Details
Full Title
ARST2531: A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
Principal Investigator
Jessica
Sun
Protocol Number
PRO00120899
NCT ID
NCT07466316
Phase
III
Enrollment Status
Open to Enrollment